Примери за използване на Studied in patients with hepatic на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Macugen has not been studied in patients with hepatic impairment.
Crizotinib dose adjustment according to Child-Pugh classification has not been studied in patients with hepatic impairment.
Humira has not been studied in patients with hepatic or renal impairment.
The use of amprenavir in combination with ritonavir has not been studied in patients with hepatic impairment.
Plegridy has not been studied in patients with hepatic impairment(see section 4.4).
Хората също превеждат
The pharmacokinetics of enfuvirtide have not been studied in patients with hepatic impairment.
AZOPT has not been studied in patients with hepatic impairment and is therefore not recommended in such patients. .
Atazanavir with ritonavir has not been studied in patients with hepatic impairment.
SIMBRINZA has not been studied in patients with hepatic impairment; caution should be used in treating such patients(see section 4.2).
EXJADE has not been studied in patients with hepatic impairment and must be used with caution in such patients. .
NEVANAC has not been studied in patients with hepatic disease or renal impairment.
The safety and efficacy of denosumab have not been studied in patients with hepatic impairment(see section 5.2).
The safety and efficacy of Kevzara have not been studied in patients with hepatic impairment, including patients with positive hepatitis B virus(HBV) or hepatitis C virus(HCV) serology(see section 4.4).
This medicinal product has not been studied in patients with hepatic impairment.
The pharmacokinetics of formoterol has not been studied in patients with hepatic impairment; however, as formoterol is primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe hepatic impairment.
However, crizotinib has not been studied in patients with hepatic impairment.
Adalimumab has not been studied in patients with hepatic or renal impairment.
The safety and efficacy of ravulizumab have not been studied in patients with hepatic impairment; however pharmacokinetic data suggest that no dose adjustment is required in patients with hepatic impairment.
Travoprost 30 µg/mL has not been studied in patients with hepatic or renal impairment.
Nelarabine has not been studied in patients with hepatic impairment.
The effect of IKERVIS has not been studied in patients with hepatic or renal impairment.
GANFORT single-dose has not been studied in patients with hepatic or renal impairment.
The medicinal product has not been studied in patients with hepatic or renal impairment.
Experience from clinical studies in patients with hepatic impairment is limited.
There is no study in patients with hepatic impairment due to cirrhosis.
Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100%.
Studies in patients with hepatic impairment have not been conducted and therefore patients with severe hepatic impairment should be treated with great caution(see section 4.4).